Related Experiment Video
Updated: Oct 25, 2025
10:02
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.3K
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study
Adrian L Oblak1,2, Peter B Lin2, Kevin P Kotredes3
1Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States.
Frontiers in Aging Neuroscience
|August 9, 2021
Summary
This study comprehensively characterizes the 5XFAD mouse model for Alzheimer's disease (AD) research. Findings enhance the development of more relevant animal models for therapeutic interventions.
Area of Science:
- Neuroscience
- Genetics
- Animal Models
Background:
- Investigating therapeutic interventions for neurodegenerative diseases requires well-characterized animal models.
- Existing Alzheimer's disease (AD) transgenic models have limitations in fully recapitulating human disease characteristics.
- The MODEL-AD consortium aims to improve AD animal models for enhanced translational value.
Purpose of the Study:
- To conduct a detailed characterization of the 5XFAD mouse model.
- To standardize the evaluation of AD mouse models for improved preclinical testing.
- To enhance the development of clinically relevant AD biomarkers and therapeutic strategies.
Main Methods:
- Transcriptomics analysis
- Electroencephalogram (EEG) recordings
- In vivo imaging techniques
- Biochemical assays
- Behavioral assessments
Main Results:
- Comprehensive data on the 5XFAD mouse model's characteristics.
- Detailed transcriptomic, EEG, imaging, biochemical, and behavioral profiles.
- Publicly available dataset through the AD Knowledge Portal.
Conclusions:
- The 5XFAD mouse model provides a valuable resource for Alzheimer's disease research.
- Standardized characterization is crucial for improving the translational validity of AD animal models.
- Enhanced animal models are essential for advancing drug design and treatment development for AD.
